Dr. Wong received his M.D. from the Johns Hopkins School of Medicine. He did a postdoctoral fellowship at the Hopkins Oncology Center under Dr. Bert Vogelstein and then held faculty positions at the Fox Chase Cancer Center and the Thomas Jefferson University before joining the Cancer Biology Program and the Dept. of Neurosurgery at Stanford University in 2005. Focusing on the causes and immunotherapy of human brain tumors, Dr. Wong has made several key discoveries, including the identification of the EGFRvIII alteration and the Gab1 signaling molecule. He showed that EGFRvIII can be used as a vaccine to treat brain tumors, which has led to several clinical trials. This led him to found the biotech company Alteris Therapeutics and as its President led its successful acquisition by Celldex Therapeutics. He has served on numerous review committees for the NIH and ACS, has been an advisor to several universities and pharmaceutical companies, and has been recognized with several honors, including Who’s Who in America, and finalist for regional Biotech Company of the Year.